Format

Send to

Choose Destination
J Invest Dermatol. 2016 Jan;136(1):24-33. doi: 10.1038/JID.2015.356.

Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options.

Author information

1
Department of Dermatology, University of Lübeck, Lübeck, Germany. Electronic address: Michael.Kasperkiewicz@uk-sh.de.
2
Department of Dermatology, University of Lübeck, Lübeck, Germany.
3
Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
4
Department of Dermatology, University of Lübeck, Lübeck, Germany; Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
5
Institute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.

Abstract

Epidermolysis bullosa acquisita (EBA) is a prototypic organ-specific autoimmune disease induced by autoantibodies to type VII collagen causing mucocutaneous blisters. In the inflammatory (bullous pemphigoid-like) EBA variant, autoantibody binding is followed by a lesional inflammatory cell infiltration, and the overall clinical picture may be indistinguishable from that of bullous pemphigoid, the latter being the most common autoimmune bullous disease. The last decade witnessed the development of several mouse models of inflammatory EBA that facilitated the elucidation of the pathogenesis of autoantibody-induced, cell-mediated subepidermal blistering diseases and identified new therapeutic targets for these and possibly other autoantibody-driven disorders.

PMID:
26763420
DOI:
10.1038/JID.2015.356
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center